Allarity Therapeutics (ALLR) Non Operating Interest Expenses (2021 - 2026)

Allarity Therapeutics (ALLR) has reported Non Operating Interest Expenses for 6 consecutive years, with $719000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses rose 5891.67% year-over-year to $719000.0; the trailing twelve-month figure through Jun 2026 stood at $1.1 million (up 448.45% YoY), and the FY2025 full-year result was $185000.0, down 71.67% from the prior year.
• Non Operating Interest Expenses rose to $719000.0 in Q2 2026 per ALLR's latest filing, from $229000.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $719000.0 in Q2 2026 and bottomed at $12000.0 in Q2 2025.
• Historically, Non Operating Interest Expenses has averaged $139277.8 across 5 years, with a median of $67000.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Non Operating Interest Expenses tumbled 97.18% in 2025, then jumped 5891.67% in 2026.
• Over 5 years, Non Operating Interest Expenses stood at $116000.0 in 2022, then surged by 98.28% to $230000.0 in 2023, then sank by 67.39% to $75000.0 in 2024, then dropped by 21.33% to $59000.0 in 2025, then jumped by 1118.64% to $719000.0 in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $719000.0, $229000.0, and $59000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.